Pembroke & Partners LLC - 08 Apr 2025 Form 4/A - Amendment Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Reporting relationship: 10%+ Owner
Issuer ticker: MTNB
Reported as of: 08 Apr 2025
Net transaction value: +$492,000
SEC form: 4/A - Amendment
Accepted by SEC: 10 Apr 2025, 13:54:22 UTC
Original report date: 25 Feb 2025
Prior SEC filing: 25 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert J. Eide

Key filing fact

Pembroke & Partners LLC filed Form 4/A - Amendment for Matinas BioPharma Holdings, Inc. (MTNB) on 10 Apr 2025.

Key facts

This page summarizes Pembroke & Partners LLC's Form 4/A - Amendment filing for Matinas BioPharma Holdings, Inc. (MTNB).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Apr 2025, 13:54.

Change

Previous filing in this sequence was filed on 25 Feb 2025.
Current net transaction value: +$492,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTNB transaction Derivative

Series C Convertible Preferred Stock

Purchase

Transaction value: $492,000
Shares: +492
Change %: +100%
Price: $1000.00^*
Shares after: 984
Date: 08 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 839,591
Exercise price: $0.5860
Footnotes: F1, F2, F3

MTNB transaction Derivative

Warrants

Purchase

Transaction value
Shares: +1,679,182
Change %: +100%
Price
Shares after: 3,358,364
Date: 08 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,679,182
Exercise price: $0.6446
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Securities Purchase Agreement, dated February 13, 2025, Pembroke purchased an aggregate of 984 shares of the Issuer's Series C Convertible Preferred Stock, par value $0.0001 per share (the "Preferred Stock") with a stated value of $1,000 per share of Preferred Stock, and 3,358,364 Warrants for gross proceeds of $984,000. The Preferred Stock and Warrants were sold in two tranches with each tranche consisting of 492 shares of Preferred Stock and 1,679,182 Warrants.

Footnote F2

Each holder of Preferred Stock is entitled to vote on an as-converted to Common Stock basis with a per share voting price of $0.6393, granting Pembroke voting power based on the Preferred Stock of up to 23% of the outstanding Common Stock. Pembroke's beneficial ownership is subject to a 9.99% limit on the shares of Common Stock issuable upon conversion of the Preferred Stock and a 4.99% limit on the shares of Common Stock issuable upon exercise of the Warrants.

Footnote F3

N/A